Effects and side effects of rosiglitazone on impaired glucose tolerance
10.3760/cma.j.issn.1008-6315.2010.09.022
- VernacularTitle:罗格列酮干预糖耐量减低疗效观察
- Author:
Yingjian LIU
- Publication Type:Journal Article
- Keywords:
Impaired glucose tolerence;
Rosiglitazone;
Intervention;
Type 2 diabetes mellitus
- From:
Clinical Medicine of China
2010;26(9):956-959
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of insulin increasing-sensitivity agent- rosiglitazone on impaired glucose tolerance. Methods One hundred and forty cases of impaired glucose tolerence(IGT)were divided into two groups randomly. Eighty cases was intervented with physical activity, diet control and rosiglitazone in the treatment group ,60 cases were intervened with physical activity and diet control in the control group for 24 weeks. Clinical characteristics, including BMI, blood pressure, blood glucose, lipids profiles, insulin, C-peptide and urinary microalbumin excretion were compared between two groups. Results In the treatment group, fasting glucose and 2 h glucose significantly decreased from (5.7 ±0.9) mmol/L and (9. 6 ± 1.8) mmol/L at the baseline to (4.6 ±0.8)mmol/L and (7. 6 ± 1.2) mmol/L(P ＜0.01). In the treatment group,the urinary micro-albumin excretion,insulin resistance,triglyceride, fasting glucose and 2 h glucose were (246 ± 16)mg/24 h,2. 024 ± 0.427, (1.6 ± 0.8)mmol/L, (4. 6 ± 0.8) mmol/L and (7. 6 ± 1.2) mmol/L, which was significantly lower than those of (280 ± 12)mg/24 h ,3. 328 ± 0.462, (2. 5 ± 0.9) mmol/L, (5.5 ± 0.7) mmol/L and (8. 9 ± 1.3) mmol/L in the control group (P ＜0.01). The treatment significantly improved the insulin sensitivity from 80 ± 1 at the baseline to 198 ±8. In the treatment, the FINS and C-peptide were significantly decreased from (32 ± 9) mU/L and (3. 58 ± 1.60) g/L at the baseline to (21 ± 8) mU/L and (2. 52 ± 1.20) g/L(P ＜ 0.01). The blood pressure deceased significantly at the 24th week, and signfiantly different from those in the conrol group (P ＜ 0.05). After 48 weeks, 1 of the patients in the treatment group developed into type 2 diabetes mellitus,whereas 8 patients developed into type 2 diabetes mellitus in the control group,which was significantly higher than that in the treatment group (P ＜0.05). The rate of side effects in the treatment group was similar with that in the control group, no liver function impair etc has been observed. Conclusions Rosiglitazone has significant effect on decreasing the blood sugar and decreasing the fasting insulin and C-peptide in patients with impaired glucose tolerancem improving the insuhn sensitivity of the circumference tissue, and can prevent or postpone the progression of IGT to type 2 diabetes mellitus in patients at risk of developing the disease.
